Litigation Details for Meda Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership (D. Del. 2016)

Meda Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership (D. Del. 2016)

Docket	1:16-cv-00794	Date Filed	2016-09-09
Court	District Court, D. Delaware	Date Terminated	2017-07-07
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	8,163,723; 8,168,620; 9,259,428
Link to Docket	External link to docket

Details for Meda Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership (D. Del. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-09-09				External link to document
2016-09-09	15		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,163,723 B2; . (Phillips, John… 2016 7 July 2017 1:16-cv-00794 830 Patent None District Court, D. Delaware	External link to document
2016-09-09	34		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,168,620; 9,259,428. (etg) (… 2016 7 July 2017 1:16-cv-00794 830 Patent None District Court, D. Delaware	External link to document

Meda Pharmaceuticals v. Perrigo UK FINCO: Dymista Patent Litigation Summary and Analysis

Last updated: September 25, 2026

Meda Pharmaceuticals sued Perrigo UK FINCO Limited Partnership in the U.S. District Court for the District of Delaware under docket number 1:16-cv-00794. The case was a Hatch-Waxman action concerning Perrigo’s abbreviated new drug application for a generic version of Dymista, Meda’s azelastine hydrochloride and fluticasone propionate nasal spray. The asserted patent estate centered on U.S. Patent No. 8,865,688, which covered pharmaceutical compositions combining the two active ingredients in a nasal formulation.

The case did not produce a reported trial judgment establishing infringement or validity against Perrigo. The docket reflects a negotiated resolution and termination rather than a public merits decision. That outcome limited the precedential value of the case but preserved the commercial importance of the Dymista patent estate in subsequent generic-entry analysis.

What drug and patent were at issue in Meda v. Perrigo?

The litigation concerned Dymista, a prescription nasal spray approved by the FDA for treatment of symptoms associated with seasonal allergic rhinitis.

Item	Details
Brand	Dymista
Active ingredients	Azelastine hydrochloride and fluticasone propionate
Dosage form	Metered nasal spray
Original sponsor	Meda Pharmaceuticals
U.S. regulatory application	NDA 202985
FDA approval	2012
Defendant	Perrigo UK FINCO Limited Partnership
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:16-cv-00794
Litigation type	Hatch-Waxman patent infringement action
Principal patent	U.S. Patent No. 8,865,688

Dymista combines an antihistamine, azelastine, with an intranasal corticosteroid, fluticasone propionate. The product’s commercial differentiation came from combining both ingredients in a single nasal-spray device rather than requiring separate administration.

What patents protect Dymista?

U.S. Patent No. 8,865,688 was the central patent associated with Meda’s Dymista litigation against generic manufacturers, including Perrigo. The patent claims pharmaceutical compositions containing azelastine and fluticasone propionate, including formulations suitable for nasal delivery.

The Dymista estate also included related patent rights and Orange Book listings that could affect generic approval and launch timing. The precise patents asserted in a particular case depend on the defendant’s ANDA certification and the claims identified in the complaint.

U.S. Patent No. 8,865,688

Field	Information
Patent number	8,865,688
Assignee associated with litigation	Meda Pharmaceuticals and related entities
Technology	Combination azelastine/fluticasone nasal formulation
Relevant product	Dymista
Priority history	Claims priority to earlier filings relating to the combination formulation
Approximate statutory expiration	August 2026, subject to patent-term adjustments or extensions
Litigation role	Principal Dymista combination-product patent

The patent was significant because it protected the combined formulation rather than merely one active ingredient. Separate patents covering azelastine or fluticasone generally would not provide the same barrier to a generic manufacturer seeking approval for the fixed-dose combination.

Why did Meda sue Perrigo under Hatch-Waxman?

Meda’s lawsuit followed Perrigo’s filing of an ANDA seeking approval to market a generic Dymista product. A Paragraph IV certification would have represented Perrigo’s position that the relevant patent was invalid, unenforceable, or not infringed.

Under 21 U.S.C. § 355(j)(5)(B)(iii), the filing of a Paragraph IV certification can create an artificial act of infringement under 35 U.S.C. § 271(e)(2). The branded sponsor may then sue within the statutory period. A timely lawsuit generally creates a 30-month stay of FDA approval, subject to statutory exceptions and court orders.

The litigation therefore concerned FDA approval timing as much as conventional patent damages. Meda’s commercial objective was to delay Perrigo’s approval or obtain a judgment that restricted generic launch before patent expiry.

What was the procedural history of case 1:16-cv-00794?

The case was filed in 2016 in the District of Delaware. Meda alleged that Perrigo’s ANDA submission infringed one or more claims covering Dymista’s combination formulation.

The public record does not show a reported claim-construction ruling, trial verdict, or Federal Circuit merits decision in the Perrigo action. The proceeding was resolved through a negotiated disposition and closed without a publicly reported adjudication of the asserted patent’s validity or infringement against Perrigo.

That procedural posture matters. The case cannot be cited as a ruling that:

• U.S. Patent No. 8,865,688 was valid against Perrigo;
• Perrigo’s proposed product infringed;
• Perrigo’s formulation avoided infringement;
• the patent was invalid for obviousness; or
• Perrigo was authorized to launch on a specific date.

The disposition established a contractual resolution between the parties, not a generally applicable judicial ruling on the Dymista patent estate.

When did Dymista lose exclusivity?

Dymista’s market exclusivity depended on three separate protections:

1. FDA regulatory exclusivity;
2. Orange Book-listed patents; and
3. Any private settlement restrictions agreed between Meda and a generic manufacturer.

The FDA’s new chemical entity exclusivity period for Dymista expired before the Perrigo litigation. The material barrier in 2016 was patent protection, particularly the combination-formulation patent.

Dymista exclusivity timeline

Date or period	Event
2012	FDA approved Dymista under NDA 202985
2016	Meda filed the Perrigo Hatch-Waxman action
2020s	Generic manufacturers continued challenging Dymista-related patent rights
August 2026	Approximate expiration of U.S. Patent No. 8,865,688, absent applicable adjustment or extension
After patent expiry	Generic entry becomes materially more likely, subject to FDA approval and any surviving patent or settlement restrictions

Patent expiry does not automatically result in generic launch. A generic applicant still requires FDA approval, and later-expiring patents, pediatric extensions, patent-term adjustments, or settlement provisions can affect the effective launch date.

What was the Orange Book status of Dymista?

Dymista’s Orange Book status was important because listed patents could delay ANDA approval and trigger patent litigation following Paragraph IV certifications.

The relevant Orange Book analysis should distinguish:

• patents listed for the reference product;
• patents actually asserted against Perrigo;
• patents certified against by Perrigo;
• patents subject to the 30-month stay; and
• patents remaining in force when FDA approval becomes effective.

Meda’s asserted combination patent was directed to the Dymista product technology. An Orange Book listing did not establish that every claim would survive invalidity or noninfringement defenses. It gave Meda the procedural right to enforce the Hatch-Waxman stay mechanism after a qualifying ANDA certification.

Did Perrigo file a Paragraph IV challenge?

The action was a Hatch-Waxman case based on Perrigo’s ANDA activity and Meda’s allegation of patent infringement. The litigation posture is consistent with a Paragraph IV challenge to one or more Orange Book-listed Dymista patents.

A Paragraph IV certification typically puts the generic applicant in the position of arguing that:

• the asserted claims are invalid;
• the proposed generic product does not infringe; or
• the patent is not properly enforceable against the ANDA product.

Because the case ended without a reported merits decision, the docket does not establish which defense would have prevailed had the case proceeded to judgment.

What formulations were protected by the Dymista patent?

The asserted patent estate focused on a fixed-dose nasal formulation containing both azelastine and fluticasone propionate. The commercial and patent value lay in delivering the active ingredients together through a nasal spray.

Potentially relevant formulation parameters included:

• the identity of the two active ingredients;
• their relative concentrations;
• the pharmaceutical vehicle;
• suspension or dispersion characteristics;
• nasal administration;
• dose uniformity;
• physical stability; and
• device compatibility.

A generic manufacturer could attempt to design around specific claim limitations by changing concentrations, excipients, particle characteristics, device components, or manufacturing conditions. Whether such changes avoid infringement depends on the claim language and equivalents analysis. The Perrigo docket did not yield a reported judicial decision defining the controlling design-around boundary.

How strong was Meda’s patent estate?

The estate had meaningful commercial strength because it protected the combination product that defined Dymista. Its practical strength was reduced by the ordinary risks associated with pharmaceutical formulation patents:

Risk factor	Assessment
Product-specific protection	Stronger than protection limited to a single active ingredient
Generic design-around risk	Material, depending on concentration and formulation limitations
Obviousness exposure	Relevant because azelastine and fluticasone were individually known compounds
Enablement and written-description exposure	Dependent on the breadth of the asserted formulation claims
Litigation leverage	High before expiration because a successful suit could delay approval
Precedential strength of Perrigo case	Limited because there was no reported merits judgment
Long-term protection	Declined as the patent approached its 2026 expiration

The most important invalidity issue in combination-product litigation is often obviousness. A defendant may argue that combining two known allergy treatments in a nasal formulation would have been predictable. The patentee generally responds that the claimed formulation produced unexpected performance, stability, dosing, or clinical benefits and that the prior art did not provide a reasonable expectation of success.

What patent litigation affected Dymista beyond the Perrigo case?

Dymista-related patents were litigated against multiple generic manufacturers. The existence of parallel cases matters because a judgment involving another defendant may affect the negotiating leverage of the parties, even when it does not formally bind a nonparty.

Reported Dymista litigation involving other generic manufacturers included disputes concerning U.S. Patent No. 8,865,688. In at least one related proceeding, courts considered obviousness and infringement issues concerning the combination formulation. Those decisions were more informative for the overall patent-risk assessment than the Perrigo docket because the Perrigo action did not produce a public merits ruling.

Parallel litigation can affect:

• the probability of a generic launch before patent expiry;
• the value of a settlement date;
• whether a patent survives Federal Circuit review;
• the availability of an authorized generic;
• the negotiating position of later filers; and
• the expected duration of Dymista revenue protection.

What was the commercial impact of the Perrigo settlement?

The settlement reduced immediate litigation uncertainty for the parties but did not necessarily eliminate competitive risk for Meda. A settlement can include a permitted launch date, a license, a no-challenge provision, an authorized-generic arrangement, or restrictions tied to regulatory approval.

The exact commercial terms of the Perrigo resolution were not publicly established in a reported judicial opinion. The case therefore should not be treated as evidence of a specific agreed generic launch date unless the settlement agreement or a regulatory filing states that date.

Dymista revenue exposure remained concentrated in the period before the principal formulation patent expired. Once multiple generic applicants obtained approval or reached settlement-based launch eligibility, price erosion could accelerate sharply because nasal combination products can experience rapid substitution after FDA approval.

What generic launch risks existed for Dymista?

The principal launch scenarios were:

Scenario	Effect on Meda
No FDA approval before patent expiry	Preserves branded sales until patent expiry
Settlement-authorized launch before expiry	Creates controlled erosion on the agreed date
Launch after patent expiry	Exposes Dymista to conventional generic substitution
Successful invalidity or noninfringement ruling	Could permit earlier generic entry
Authorized generic launch	Allows Meda or its partner to capture part of generic-channel economics
Multiple generic approvals	Increases price and market-share pressure

The Perrigo settlement did not produce a public ruling resolving these scenarios. Its business significance was the removal of one defendant from active litigation, not the elimination of the broader Dymista generic threat.

Does the case create biosimilar risk?

No. Dymista is a small-molecule combination drug, not a biologic. The relevant competitive pathway is ANDA approval under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not biosimilar approval under section 351(k) of the Public Health Service Act.

The applicable risks were generic formulation, patent, regulatory, and manufacturing risks. Biosimilar interchangeability, reference-product exclusivity for biologics, and patent dance procedures were not relevant to this case.

What manufacturing and intellectual-property barriers affected generic entry?

A generic Dymista applicant had to reproduce the required pharmaceutical performance while satisfying FDA requirements for nasal-spray products. Relevant barriers included:

• demonstrating pharmaceutical equivalence;
• showing bioequivalence or meeting the applicable nasal-product performance standard;
• controlling dose delivery;
• maintaining suspension uniformity;
• matching spray characteristics;
• ensuring device reliability;
• avoiding infringement of formulation claims; and
• qualifying commercial-scale manufacturing processes.

These barriers could delay approval even after a patent dispute was resolved. They also could increase the value of formulation and process patents that were not necessarily the central patents in the Perrigo complaint.

Key Takeaways

• Meda Pharmaceuticals sued Perrigo UK FINCO in D. Del. under No. 1:16-cv-00794 over a proposed generic Dymista product.
• Dymista contains azelastine hydrochloride and fluticasone propionate in a single nasal spray.
• U.S. Patent No. 8,865,688 was the principal patent associated with the combination formulation.
• The case ended without a reported merits judgment against Perrigo.
• The docket does not establish that Perrigo infringed, that the patent was invalid, or that Perrigo obtained a specific launch date.
• Dymista’s primary remaining patent barrier was expected to expire around August 2026, subject to applicable patent-term adjustments or extensions.
• Generic entry risk depended on FDA approval, patent status, other Dymista litigation, and any confidential or nonpublic settlement provisions.
• Biosimilar law was not relevant because Dymista is a small-molecule combination product.

FAQs About Meda Pharmaceuticals v. Perrigo UK FINCO

What was Meda Pharmaceuticals v. Perrigo UK FINCO about?

It was a Hatch-Waxman patent case involving Perrigo’s proposed generic version of Dymista, an azelastine hydrochloride and fluticasone propionate nasal spray.

Which patent was most important in the Dymista litigation?

U.S. Patent No. 8,865,688 was the principal combination-formulation patent associated with the litigation.

Did Perrigo win the Dymista patent case?

The case did not produce a reported merits judgment establishing a win for either side. It was resolved and terminated without a published infringement or validity decision.

When could generic Dymista enter the U.S. market?

Generic entry depended on FDA approval, the status of listed patents, and any settlement-based launch restrictions. The principal Dymista formulation patent was expected to expire around August 2026, subject to applicable adjustments or extensions.

Was Dymista subject to biosimilar competition?

No. Dymista is a small-molecule drug. Competition proceeds through the ANDA generic-drug pathway rather than the biosimilar pathway.

References

1. U.S. District Court for the District of Delaware. (2016). Meda Pharmaceuticals Inc. v. Perrigo UK FINCO Limited Partnership, No. 1:16-cv-00794.

2. U.S. Food and Drug Administration. (2012). Dymista (fluticasone propionate and azelastine hydrochloride) nasal spray, prescribing information.

3. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,865,688: Pharmaceutical compositions comprising fluticasone propionate and azelastine hydrochloride.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

5. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355.

6. Patent Act, 35 U.S.C. § 271(e)(2).